Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma

BACKGROUND: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Transl Med
Egile Nagusiak: Yousef, Sara, Heise, Johanna, Lajmi, Nesrine, Bartels, Katrin, Kröger, Nicolaus, Luetkens, Tim, Atanackovic, Djordje
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4474344/
https://ncbi.nlm.nih.gov/pubmed/26088750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0562-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak